Thrombotic Thrombocytopenic Purpura and Hemolytic-Uremic Syndrome

Thrombotic Thrombocytopenic Purpura and Hemolytic-Uremic Syndrome is a topic covered in the Washington Manual of Medical Therapeutics.

To view the entire topic, please or .

The Washington Manual is an award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Explore these free sample topics:

-- The first section of this topic is shown below --

General Principles

Definition

Thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS) are thrombotic microangiopathies (TMAs) caused by platelet–vWF aggregates and platelet–fibrin aggregates, respectively, resulting in thrombocytopenia, microangiopathic hemolytic anemia (MAHA), and organ ischemia. Usually, clinical and laboratory features permit differentiation of TTP from HUS. TMA may also occur in association with DIC, HIV infection, malignant hypertension, vasculitis, organ and stem cell transplant–related toxicity, adverse drug reactions, and pregnancy-related complications of preeclampsia/eclampsia and HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome.

Epidemiology

Acquired TTP has an incidence of approximately 11.3 cases per 106 persons, occurring more frequently in women and African Americans.1 Typical HUS usually occurs in gastroenteritis outbreaks affecting children. Adults may present with both typical and atypical (non–gastroenteritis-associated) variants of HUS.

Etiology

  • Autoantibody-mediated removal of plasma vWF-cleaving protease, A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13), leading to elevated levels of abnormally large vWF multimers, causes acquired TTP.2 The abnormal vWF multimers spontaneously adhere to platelets and may produce occlusive vWF–platelet aggregates in the microcirculation and subsequent microangiopathy. Second-hit events may involve endothelial dysfunction or injury.
  • Typical or enteropathic HUS has an association with Escherichia coli (O157:H7) production of Shiga-like toxins in Shiga toxigenic E. coli HUS (STEC-HUS).
  • HUS can also be associated with transplant, endothelial-damaging drugs, and pregnancy.3
  • Inherited or acquired defects in regulation of the alternative complement pathway are present in 30%–50% of atypical HUS cases.3

-- To view the remaining sections of this topic, please or --

General Principles

Definition

Thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS) are thrombotic microangiopathies (TMAs) caused by platelet–vWF aggregates and platelet–fibrin aggregates, respectively, resulting in thrombocytopenia, microangiopathic hemolytic anemia (MAHA), and organ ischemia. Usually, clinical and laboratory features permit differentiation of TTP from HUS. TMA may also occur in association with DIC, HIV infection, malignant hypertension, vasculitis, organ and stem cell transplant–related toxicity, adverse drug reactions, and pregnancy-related complications of preeclampsia/eclampsia and HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome.

Epidemiology

Acquired TTP has an incidence of approximately 11.3 cases per 106 persons, occurring more frequently in women and African Americans.1 Typical HUS usually occurs in gastroenteritis outbreaks affecting children. Adults may present with both typical and atypical (non–gastroenteritis-associated) variants of HUS.

Etiology

  • Autoantibody-mediated removal of plasma vWF-cleaving protease, A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13), leading to elevated levels of abnormally large vWF multimers, causes acquired TTP.2 The abnormal vWF multimers spontaneously adhere to platelets and may produce occlusive vWF–platelet aggregates in the microcirculation and subsequent microangiopathy. Second-hit events may involve endothelial dysfunction or injury.
  • Typical or enteropathic HUS has an association with Escherichia coli (O157:H7) production of Shiga-like toxins in Shiga toxigenic E. coli HUS (STEC-HUS).
  • HUS can also be associated with transplant, endothelial-damaging drugs, and pregnancy.3
  • Inherited or acquired defects in regulation of the alternative complement pathway are present in 30%–50% of atypical HUS cases.3

There's more to see -- the rest of this topic is available only to subscribers.